Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Clinical Trials
Online First
Real-World Noninterventional Studies: Multiple Myeloma Paves the Way for Improved Clinical Trial Design
By
Robert M. Rifkin, MD, FACP
Clinical Trials
,
Multiple Myeloma
June 2021, Vol 12, No 3
According to the American Cancer Society, nearly 35,000 new patients with multiple myeloma are diagnosed annually in the United States, with more than 12,000 deaths attributed to this cancer. However, with the introduction of several novel therapies, the outcomes for patients with newly diagnosed multiple myeloma have improved substantially over the past decade.
Read Article
New Research Highlights Barriers to Clinical Trial Participation
By
Chase Doyle
Clinical Trials
December 2020, Vol 11, No 6
Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. The numbers are even lower among minority adolescent and young adults (AYAs).
Read Article
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
By
Chase Doyle
Clinical Trials
,
Personalized Medicine
October 2019, Vol 10, No 5
San Diego, CA—New research sponsored by the National Cancer Institute highlights the uphill battle faced by patients with limited financial resources even in clinical trials. According to data presented at the 2019 ASCO Quality Care Symposium, patients with Medicaid or with no insurance had significantly worse overall survival in positive clinical trials compared with privately insured patients.
Read Article
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
By
Wayne Kuznar
Clinical Trials
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Increasing Patient Enrollment in Clinical Trials Key to Progress in Cancer Care
By
Jessica Miller
Clinical Trials
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Patient involvement in clinical trials will impact the Cancer Moonshot’s goal of achieving 10 years of progress in 5 years’ time, said Kim Thiboldeaux, Chief Executive Officer, Cancer Support Community, Washington, DC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
RAF Family Inhibitor Has Preliminary Activity in Multiple Tumor Types
By
Charles Bankhead
Clinical Trials
July 2016, Vol 7, No 6
The multitargeted RAF inhibitor BGB-283 demonstrated activity in several types of advanced solid tumors associated with different mutations in the RAF family of genes, results of a preliminary clinical trial showed.
Read Article
Trials and Tribulations: Reporting Clinical Trial Results Is a Legal and Ethical Duty
By
Kristen Chanley
Clinical Trials
July 2016, Vol 7, No 6
Susan Gubar, an ovarian cancer survivor whose life has been extended by a clinical trial, was shocked to read a recent article published online by Charles Piller on the lack of reporting of clinical trial results.
Read Article
End Points in Oncology Clinical Trials: Revisiting Overall Survival
By
Ryan Saadi, MD, MPH
Clinical Trials
August 2014, Vol 5, No 6
When a promising investigational cancer drug enters a development area of great medical need, there is high pressure on the manufacturer from patients and from physicians to quickly secure patient access to this drug.
Read Article
Clinical Trials: Understanding Cost, Coverage Implications
Clinical Trials
July/August 2010, Vol 1, No 3
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma